Sandoz Attacks Amgen Over US Enbrel Exclusivity
Firm Claims $1bn+ In Lost Biosimilar Sales As It Attacks ‘Scheming’ Originator
Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."
